Katarzyna W.
- Country
- Poland
- Department
- n/a
Research Overview
- Evaluation of Afimetoran Efficacy and Safety in Active Systemic Lupus Erythematosus: A Phase 2 Randomized, Double-blind, Placebo-Controlled Study
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)
Data & Insights
Has run more than one trial at 3 of 54 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in treating Systemic Lupus Erythematosus (SLE), conducting research into novel therapeutic approaches for managing this complex autoimmune condition.
- Active SLE Management
- Disease Activity Assessment
- Innovative Treatment Modalities
Key focus includes evaluating therapeutic interventions for patients with active manifestations of lupus.
Clinical Assessment
Expertise in utilizing advanced clinical assessment tools including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and SLE Responder Index for evaluating treatment effectiveness.
- Disease Activity Monitoring
- Treatment Response Assessment
- Clinical Outcomes Evaluation
Specializes in measuring and tracking lupus disease progression and treatment outcomes.
Therapeutic Development
Active involvement in evaluating emerging treatments including novel immunomodulatory agents for SLE, focusing on both efficacy and safety profiles in clinical applications.
- Targeted Therapy Assessment
- Safety Profile Evaluation
- Treatment Optimization
Dedicated to advancing therapeutic options for patients with active lupus manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.